Welcome to our dedicated page for ARS Pharms SEC filings (Ticker: SPRY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ARS Pharmaceuticals, Inc. filings document the public-company record for a biopharmaceutical issuer commercializing neffy, an epinephrine nasal spray for severe allergic reactions and anaphylaxis. The company’s 8-K filings report financial results, Regulation FD presentation updates, material agreements, product and commercialization disclosures, and legal or regulatory events involving neffy and related patent protections.
ARS Pharmaceuticals’ proxy materials describe board elections, shareholder voting matters, executive compensation, equity awards and audit oversight. Other filings identify its Nasdaq-listed common stock, capital-structure matters, credit arrangements involving ARS Pharmaceuticals Operations, Inc., and risk-related disclosures tied to product development, commercialization, intellectual property and regulatory pathways.
ARS Pharmaceuticals (Nasdaq: SPRY) filed an 8-K disclosing the voting results of its 2025 Annual Meeting held on June 25, 2025.
- All four Class II director nominees—Richard Lowenthal, Peter Kolchinsky, Brenton Saunders and Peter Thompson—were elected to serve until the 2028 meeting.
- Shareholders ratified Ernst & Young LLP as independent auditor for fiscal 2025 with 77,258,380 votes for (≈99.5%).
No other proposals were considered and the disclosure contains no material changes to strategy, operations or financial outlook.
ARS Pharmaceuticals, Inc. (SPRY) – Form 4 insider transaction
Chief Commercial Officer Eric Karas exercised 15,000 stock options at an exercise price of $1.50 on 06/18/2025 (Code M) and simultaneously sold 15,000 common shares at $16.00 per share (Code S) under a Rule 10b5-1 trading plan adopted on 03/26/2024. Following these transactions, Karas directly holds 7,696 common shares and retains 559,588 outstanding options. No other derivative or non-derivative changes were reported.
The filing indicates routine option exercise and sale rather than an outright reduction of economic exposure, as the officer continues to hold a substantial option position. Investors may view the scheduled nature of the sale as mitigating potential negative sentiment typically associated with insider selling.